Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Alcon

Status and phase

Terminated

Phase 4

Conditions

Intraocular Pressure

Treatments

Drug: Travoprost 0.004% + Brinzolamide 1.0%

Drug: Travoprost 0.004% + Tears Natural

Study type

Interventional

Funder types

Industry

Identifiers

NCT00758342

MS-06-01

Details and patient eligibility

About

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

Enrollment

37 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 18 years;
CACG (Chronic Angle Closure Glaucoma) ≥ 1eye
have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes
clinical stability of VA (Visual Acuity) and optic nerve throughout the study

Exclusion criteria

Abnormality restricts exam of the fundus or anderior chamber
conjunctivitis, keratitis or uveitis
unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks
ocular surgery prior to the study